Literature DB >> 31726042

Long-term effects of the glucocorticoid receptor modulator CORT113176 in murine motoneuron degeneration.

Maria Meyer1, Maria Sol Kruse1, Laura Garay2, Analia Lima1, Paulina Roig1, Hazel Hunt3, Joseph Belanoff3, E Ronald de Kloet4, Maria Claudia Gonzalez Deniselle5, Alejandro F De Nicola6.   

Abstract

The Wobbler mouse spinal cord shows vacuolated motoneurons, glial reaction, inflammation and abnormal glutamatergic parameters. Wobblers also show deficits of motor performance. These conditions resemble amyotrophic lateral sclerosis (ALS). Wobbler mice also show high levels of corticosterone in blood, adrenals and brain plus adrenal hypertrophy, suggesting that chronically elevated glucocorticoids prime spinal cord neuroinflammation. Therefore, we analyzed if treatment of Wobbler mice with the glucocorticoid receptor (GR) antagonist CORT113176 mitigated the mentioned abnormalities. 30 mg/kg CORT113176 given daily for 3 weeks reduced motoneuron vacuolation, decreased astro and microgliosis, lowered the inflammatory mediators high mobility group box 1 protein (HMGB1), toll-like receptor 4, myeloid differentiation primary response 88 (MyD88), p50 subunit of nuclear factor kappa B (NFκB), tumor necrosis factor (TNF) receptor, and interleukin 18 (IL18) compared to untreated Wobblers. CORT113176 increased the survival signal pAKT (serine-threonine kinase) and decreased the death signal phosphorylated Junk-N-terminal kinase (pJNK), symptomatic of antiapoptosis. There was a moderate positive effect on glutamine synthase and astrocyte glutamate transporters, suggesting decreased glutamate excitotoxicity. In this pre-clinical study, Wobblers receiving CORT113176 showed enhanced resistance to fatigue in the rota rod test and lower forelimb atrophy at weeks 2-3. Therefore, long-term treatment with CORT113176 attenuated degeneration and inflammation, increased motor performance and decreased paw deformity. Antagonism of the GR may be of potential therapeutic value for neurodegenerative diseases.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Glucocorticoid receptor antagonist; Motor behavior; Neuroinflammation; Wobbler mouse

Mesh:

Substances:

Year:  2019        PMID: 31726042     DOI: 10.1016/j.brainres.2019.146551

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform.

Authors:  Frank W Pun; Bonnie Hei Man Liu; Xi Long; Hoi Wing Leung; Geoffrey Ho Duen Leung; Quinlan T Mewborne; Junli Gao; Anastasia Shneyderman; Ivan V Ozerov; Ju Wang; Feng Ren; Alexander Aliper; Evelyne Bischof; Evgeny Izumchenko; Xiaoming Guan; Ke Zhang; Bai Lu; Jeffrey D Rothstein; Merit E Cudkowicz; Alex Zhavoronkov
Journal:  Front Aging Neurosci       Date:  2022-06-28       Impact factor: 5.702

Review 2.  Little Helpers or Mean Rogue-Role of Microglia in Animal Models of Amyotrophic Lateral Sclerosis.

Authors:  Hilal Cihankaya; Carsten Theiss; Veronika Matschke
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

3.  NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke.

Authors:  Xin-Xin Wang; Fan Wang; Guang-Hui Mao; Jun-Chao Wu; Mei Li; Rong Han; Jing She; Rong Zhang; Rui Sheng; Zhong Chen; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2021-06-24       Impact factor: 6.150

Review 4.  Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases.

Authors:  Alejandro F De Nicola; Maria Meyer; Rachida Guennoun; Michael Schumacher; Hazel Hunt; Joseph Belanoff; E Ronald de Kloet; Maria Claudia Gonzalez Deniselle
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.